Asst. Prof. Li, Yinghui
My group's research interest is to understand the mechanisms by which deregulated oncogenic signalling pathways alter the cancer cell epigenome and transcriptome to drive cancer progression. The long-term goal of our research is to uncover effective therapeutic targets for malignant cancers through disrupting specific gene regulatory mechanisms or target gene function downstream of oncogenic signalling. There are two major themes of my current research. The first one is to study the involvement of pro-inflammatory signalling, specifically the non-canonical NF-κB and TWEAK/Fn14 signalling pathways, in the activation of cis-regulatory drivers of cancers. The second one is to study how NF-κB/p52 associated long noncoding RNAs or lincRNAs interact with transcription factors or chromatin regulators to mediate oncogenic functions and develop strategies to target such interactions.
Research Areas
Research Fellow
Project Officer
MSc Student
- Ang, D.A., Harmston, N., and Li, Y. (2025) ATF4:p52 complex activates oncogenic enhancers in multiple myeloma via p300/CBP recruitment to regulate BACH1. Cancer Letters 623, 217727. https://doi.org/10.1016/j.canlet.2025.217727
- Sim, N., Carter, J.M., Deka, K., Sim, Y., Tan, K.T.B., Tan, S.M., and Li, Y. (2024) TWEAK/Fn14 signalling driven super-enhancer reprogramming promotes pro-metastatic metabolic rewiring in Triple-Negative Breast Cancer. Nature Communications 15, 5638. https://doi.org/10.1038/s41467-024-50071-z
- Ang, D.A., Carter, J.M., Deka, K., Tan, J.H.L., Zhou, J., Chen, Q., Chng, W.J., Harmston, N., and Li, Y. (2024) Aberrant non-canonical NF-κB signalling reprograms the epigenome landscape to drive oncogenic transcriptomes in multiple myeloma. Nature Communications 15, 2513. https://doi.org/10.1038/s41467-024-46728-4
- Sim, N., and Li, Y. (2023) NF-κB/p52 augments ETS1 binding genome-wide to promote glioma progression. Communications Biology 6(1), 445. https://doi.org/10.1038/s42003-023-04821-2
- Lim, S.K., Peng, C.C., Low, S., Vijay, V., Budiman, A., Phang, B.H., Lim, J.Q., Jeyasekharan, A.D., Lim, S.T., Ong, C.K., Tan, S.M., and Li, Y. (2022) Sustained activation of non-canonical NF-κB signalling drives glycolytic reprogramming in doxorubicin-resistant DLBCL. Leukemia 37, 441–452. https://doi.org/10.1038/s41375-022-01769-w